Premium
Pharmacogenomics guidelines: Current status and future development
Author(s) -
Guo Chengxian,
Xie Xiaoxue,
Li Jingao,
Huang Lihua,
Chen Shaojun,
Li Xi,
Yi Xin,
Wu Qin,
Yang Guoping,
Zhou Honghao,
Liu JunPing,
Chen Xiang
Publication year - 2019
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/1440-1681.13097
Subject(s) - pharmacogenomics , pharmacogenetics , drug response , medicine , natural product research , drug development , drug , pharmacology , biology , genotype , genetics , pharmacognosy , gene , biological activity , in vitro
Genetic polymorphisms impact biological responses to drugs. Current pharmacogenomics guidelines formulated by different countries, such as the Clinical Pharmacogenetics Implementation Consortium, the Dutch Pharmacogenetics Working Group, the Canadian Pharmacogenomics Network for Drug Safety, and the French National Network (Réseau) of Pharmacogenetics, play important roles in clinical practices. However, the standards for these guidelines vary significantly, resulting in differences in recommendations. The present article discusses these differences by head‐to‐head comparison of the existing pharmacogenomics guidelines and proposes new strategies for their future development.